These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28061447)

  • 1. The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.
    Li X; Yin X; Wang H; Huang J; Yu M; Ma Z; Li C; Zhou Y; Yan X; Huang S; Jin J
    Oncotarget; 2017 Feb; 8(8):12764-12774. PubMed ID: 28061447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
    Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
    Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.
    Lam SS; Ho ES; He BL; Wong WW; Cher CY; Ng NK; Man CH; Gill H; Cheung AM; Ip HW; So CC; Tamburini J; So CW; Ho DN; Au CH; Chan TL; Ma ES; Liang R; Kwong YL; Leung AY
    Sci Transl Med; 2016 Oct; 8(359):359ra129. PubMed ID: 27708062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
    Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.
    Qian Y; Zhang X; Mao S; Wei W; Lin X; Ling Q; Ye W; Li F; Pan J; Zhou Y; Zhao Y; Huang X; Huang J; Tong H; Sun J; Jin J
    Mol Oncol; 2023 Jul; 17(7):1402-1418. PubMed ID: 36567628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
    Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
    J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
    PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
    Wu M; Li L; Hamaker M; Small D; Duffield AS
    Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
    Pillinger G; Abdul-Aziz A; Zaitseva L; Lawes M; MacEwan DJ; Bowles KM; Rushworth SA
    Sci Rep; 2015 Aug; 5():12949. PubMed ID: 26292723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
    Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
    Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW; Wang AN; Liao HA; Chen CY; Hou HA; Hu CY; Tien HF; Ou DL; Lin LI
    Cancer Lett; 2016 Jul; 376(2):218-25. PubMed ID: 27060207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
    Song G; Valdez BC; Li Y; Liu Y; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1687-95. PubMed ID: 25111583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
    Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH
    Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification.
    Tian T; Li J; Li Y; Lu YX; Tang YL; Wang H; Zheng F; Shi D; Long Q; Chen M; Garcia-Manero G; Hu Y; Qin L; Deng W
    Theranostics; 2019; 9(13):3768-3779. PubMed ID: 31281512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
    Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
    J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
    Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.
    Wu H; Hu C; Wang A; Weisberg EL; Wang W; Chen C; Zhao Z; Yu K; Liu J; Wu J; Nonami A; Wang L; Wang B; Stone RM; Liu S; Griffin JD; Liu J; Liu Q
    Leukemia; 2016 Mar; 30(3):754-7. PubMed ID: 26139428
    [No Abstract]   [Full Text] [Related]  

  • 18. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 19. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
    Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
    Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3-ITD-driven acute myeloid leukemia.
    Lopez-Reyes RG; Quinet G; Gonzalez-Santamarta M; Larrue C; Sarry JE; Rodriguez MS
    FEBS Open Bio; 2021 Jan; 11(1):48-60. PubMed ID: 33410599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.